Financial Survey: GENFIT S A/ADR (NASDAQ:GNFT) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

GENFIT S A/ADR (NASDAQ:GNFT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Valuation & Earnings

This table compares GENFIT S A/ADR and BioCryst Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GENFIT S A/ADR N/A N/A N/A N/A N/A
BioCryst Pharmaceuticals $20.65 million 18.11 -$101.25 million ($0.98) -3.46



GENFIT S A/ADR has higher earnings, but lower revenue than BioCryst Pharmaceuticals.

Insider and Institutional Ownership

15.3% of GENFIT S A/ADR shares are owned by institutional investors. Comparatively, 92.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 5.2% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares GENFIT S A/ADR and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GENFIT S A/ADR N/A N/A N/A
BioCryst Pharmaceuticals -472.12% -223.34% -71.72%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for GENFIT S A/ADR and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENFIT S A/ADR 0 0 5 0 3.00
BioCryst Pharmaceuticals 0 4 5 0 2.56

GENFIT S A/ADR currently has a consensus price target of $52.62, indicating a potential upside of 155.67%. BioCryst Pharmaceuticals has a consensus price target of $9.64, indicating a potential upside of 184.45%. Given BioCryst Pharmaceuticals’ higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than GENFIT S A/ADR.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.